Published in Cancer Immunol Immunother on July 26, 2011
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med (2012) 2.11
Th9 cells promote antitumor immune responses in vivo. J Clin Invest (2012) 1.80
Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity (2012) 1.24
The development and in vivo function of T helper 9 cells. Nat Rev Immunol (2015) 1.18
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front Oncol (2015) 1.01
Context and location dependence of adaptive Foxp3(+) regulatory T cell formation during immunopathological conditions. Cell Immunol (2012) 0.86
Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. PLoS One (2014) 0.83
Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges. Cancer Res (2014) 0.82
Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses. PLoS One (2013) 0.80
A deleterious role for Th9/IL-9 in hepatic fibrogenesis. Sci Rep (2016) 0.79
Amazing IL-9: revealing a new function for an "old" cytokine. J Clin Invest (2012) 0.79
4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression. PLoS One (2016) 0.78
Association between low expression levels of interleukin-9 and colon cancer progression. Exp Ther Med (2015) 0.78
Interleukin-9 Promotes Pancreatic Cancer Cells Proliferation and Migration via the miR-200a/Beta-Catenin Axis. Biomed Res Int (2017) 0.75
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
Regulatory T cells and immune tolerance. Cell (2008) 18.77
A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 11.48
TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol (2005) 7.44
Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol (2008) 6.76
The plasticity of dendritic cell responses to pathogens and their components. Science (2001) 5.58
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 5.31
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med (2009) 2.78
IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity (2000) 2.74
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Toll receptors and pathogen resistance. Cell Microbiol (2003) 2.56
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol (2008) 2.50
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med (2008) 2.46
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood (2004) 2.38
Toll-like receptors as adjuvant receptors. Biochim Biophys Acta (2002) 2.20
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol (2007) 1.92
Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol (2002) 1.92
Cellular sources and immune functions of interleukin-9. Nat Rev Immunol (2010) 1.92
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol (2003) 1.54
IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune suppression. J Immunol (2010) 1.52
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol (2009) 1.32
Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. J Immunol (2009) 1.22
Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol (2010) 1.21
Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther (2009) 1.16
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol (2004) 1.08
4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity. Eur J Immunol (2002) 1.07
Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res (2008) 1.06
Engagement of 4-1BB inhibits the development of experimental allergic conjunctivitis in mice. J Immunol (2005) 1.04
A non-redundant role for OX40 in the competitive fitness of Treg in response to IL-2. Eur J Immunol (2010) 1.02
Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer. Immunol Lett (2007) 1.01
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer (2005) 1.00
Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol (2003) 0.99
CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother (2007) 0.92
The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res (2009) 0.92
Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J Immunol (2006) 0.90
Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res (2008) 0.90
Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. Cancer Res (2003) 0.85
Regulatory T cells and antigen-specific tolerance. Chem Immunol Allergy (2008) 0.85
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34
Retracted Foxp3-positive macrophages display immunosuppressive properties and promote tumor growth. J Exp Med (2011) 3.15
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol (2011) 2.69
Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med (2009) 2.17
Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol (2006) 1.99
Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res (2006) 1.66
High accumulation of T regulatory cells prevents the activation of immune responses in aged animals. J Immunol (2006) 1.65
Th2 cytokines are associated with reduced worm burdens in a human intestinal helminth infection. J Infect Dis (2003) 1.64
Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun (2004) 1.49
IL-9 promotes IL-13-dependent paneth cell hyperplasia and up-regulation of innate immunity mediators in intestinal mucosa. J Immunol (2009) 1.48
The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol (2003) 1.47
MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther (2007) 1.33
Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines. BMC Genomics (2008) 1.28
IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol (2010) 1.25
Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol (2010) 1.21
Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. J Allergy Clin Immunol (2012) 1.17
The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion. Int J Cancer (2010) 1.12
The many lives of IL-9: a question of survival? Nat Immunol (2012) 1.11
Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci (2007) 1.11
Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol (2004) 1.09
The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur J Immunol (2004) 1.08
Systemic targeting of CpG-ODN to the tumor microenvironment with anti-neu-CpG hybrid molecule and T regulatory cell depletion induces memory responses in BALB-neuT tolerant mice. Cancer Res (2008) 1.06
Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther (2009) 1.06
CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Eur J Immunol (2003) 1.06
Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res (2011) 1.05
IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol (2009) 1.04
Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Gerontol (2005) 1.04
TGF-β interactions with IL-1 family members trigger IL-4-independent IL-9 production by mouse CD4(+) T cells. Eur J Immunol (2010) 1.02
Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer (2005) 1.00
IL-9 promotes but is not necessary for systemic anaphylaxis. J Immunol (2005) 0.96
IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol (2005) 0.96
Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Mol Immunol (2012) 0.94
T cell-derived IL-17 mediates epithelial changes in the airway and drives pulmonary neutrophilia. J Immunol (2013) 0.92
IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytes through TGF-beta. J Immunol (2002) 0.92
CpG-ODN but not other TLR-ligands restore the antitumor responses in old mice: the implications for vaccinations in the aged. Cancer Immunol Immunother (2007) 0.92
Interferon-γ orchestrates the number and function of Th17 cells in experimental autoimmune encephalomyelitis. J Interferon Cytokine Res (2011) 0.92
Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration. Microvasc Res (2005) 0.91
ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis. J Clin Immunol (2009) 0.90
Implications of aging and self-tolerance on the generation of immune and antitumor immune responses. Cancer Res (2008) 0.90
Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol (2006) 0.89
Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol (2012) 0.89
Interleukin-9 promotes eosinophilic rejection of mouse heart allografts. Transplantation (2003) 0.89
Immunity, cancer and aging: lessons from mouse models. Aging Dis (2011) 0.89
CXCL6 antibody neutralization prevents lung inflammation and fibrosis in mice in the bleomycin model. J Leukoc Biol (2013) 0.87
Comparative kinetic analyses of gene profiles of naïve CD4+ and CD8+ T cells from young and old animals reveal novel age-related alterations. Aging Cell (2011) 0.87
Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine (2009) 0.85
Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice. Cancer Res (2003) 0.85
Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-γ. Arthritis Rheumatol (2014) 0.85
Impact of aging on cancer immunity and immunotherapy. Cancer Immunol Immunother (2009) 0.85
Differential gene expression in auristatin PHE-treated Cryptococcus neoformans. Antimicrob Agents Chemother (2004) 0.85
In vivo maturation of T(H) cells in relation to atopy. J Allergy Clin Immunol (2011) 0.84
Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice. Clin Vaccine Immunol (2010) 0.83
Dual TCR expression biases lung inflammation in DO11.10 transgenic mice and promotes neutrophilia via microbiota-induced Th17 differentiation. J Immunol (2011) 0.83
Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells. Eur Cytokine Netw (2005) 0.83
Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity. Cancer Immunol Immunother (2012) 0.82
Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol (2004) 0.82
Characterization of p40 and IL-10 in the BALF of patients with pulmonary sarcoidosis. J Interferon Cytokine Res (2003) 0.81
IL-9 enhances growth of ICC, maintains network structure and strengthens rhythmicity of contraction in culture. J Cell Mol Med (2006) 0.81
Divergent roles of IFNs in the sensitization to endotoxin shock by lactate dehydrogenase-elevating virus. Int Immunol (2007) 0.81
Autocrine stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/I-309. Oncogene (2004) 0.80
Amine-reactive OVA multimers for auto-vaccination against cytokines and other mediators: perspectives illustrated for GCP-2 in L. major infection. J Leukoc Biol (2011) 0.80
rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer. Viral Immunol (2008) 0.80
Dexamethasone inhibits IL-9 production by human T cells. J Inflamm (Lond) (2005) 0.79
Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis. Cancer Lett (2011) 0.78
IL-27p28 is essential for parent-to-F1 acute graft-versus-host disease. Eur J Immunol (2014) 0.77
Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults. Curr Med Chem (2016) 0.77
Anti-cytokine auto-vaccinations as tools for the analysis of cytokine function in vivo. Cytokine Growth Factor Rev (2012) 0.77
Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy. Proc Natl Acad Sci U S A (2014) 0.76
The roles of epithelial-mesenchymal interactions and the innate immune response on the tumorigenicity of human prostate carcinoma cell lines grown in immuno-compromised mice. In Vivo (2003) 0.76
Cancer immunotherapy: focusing on the young, neglecting the old. Future Oncol (2010) 0.76
Characterization of the T-lymphocyte response elicited by mouse immunization with rat platelets. Exp Hematol (2011) 0.75
Production, purification and biological characterization of mono-PEGylated anti-IL-17A antibody fragments. Int J Pharm (2013) 0.75
Changes in antibody specificities and cytokine release after infection with lactate dehydrogenase-elevating virus. Int Immunopharmacol (2013) 0.75
Measurement of mouse and human interleukin 9. Curr Protoc Immunol (2002) 0.75